Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. -., . . . Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of oncology, 33(11), . https://doi.org/10.1016/j.annonc.2022.07.1940
Chicago-Zitierstil (17. Ausg.)Loibl, Sibylle, et al. "Neoadjuvant Durvalumab Improves Survival in Early Triple-negative Breast Cancer Independent of Pathological Complete Response." Annals of Oncology 33, no. 11 (2022). https://doi.org/10.1016/j.annonc.2022.07.1940.
MLA-Zitierstil (9. Ausg.)Loibl, Sibylle, et al. "Neoadjuvant Durvalumab Improves Survival in Early Triple-negative Breast Cancer Independent of Pathological Complete Response." Annals of Oncology, vol. 33, no. 11, 2022, https://doi.org/10.1016/j.annonc.2022.07.1940.